化合物信息

S2665 

Research Area: Cardiovascular Disease
Biological Activity:
Ciprofibrate is a peroxisome proliferator-activated receptor agonist. [1] It was reported that ciprofibrate decreased the levels of plasma triglycerides and total cholesterol as well as low-density lipoprotein cholesterol. Meanwhile, ciprofibrate elevated plasma levels of high-density lipoprotein cholesterol. The maximum concentration time of ciprofibrate is between one hour and 2.5 hours while the long half life (80 -100 h) permits daily dosing of the drug. In addition, the maximum plasma concentration is between 66 and 88 μg/mL after chronic administration of 100 mg/day of ciprofibrate. Ciprofibrate belongs to the second generation of fibric acid derivatives which used to treat patients with dyslipidaemias of various types. [2]

C0330 

Biochem/physiol Actions
Peroxisome proliferator-activated receptor α (PPARα) agonist
Other Notes
Tandem Mass Spectrometry data independently generated by Scripps Center for Metabolomics is available to view or download in PDF. C0330.pdf Tested metabolites are featured on Scripps Center for Metabolomics METLIN Metabolite Database. To learn more, visit sigma.com/metlin.

C482475 

Ciprofibrate is a hypolipemic agent, related structurally to Clofibrate (C586910). Ciprofibrate is used as an antilipemic.